Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
ANIP
Strong BuyFull HouseAPPROVEANI Pharmaceuticals, Inc. · Healthcare · United States · $1.7B · Avg Vol: $27M/d
ANI Pharmaceuticals combines a generics and established-brands base with a growing rare-disease franchise, giving it a reasonable quality score (Q70) and strong momentum as the rare-disease products scale. The small insider selling is routine. Nothing adverse is known on accounting, solvency or governance.
COMPANY DESCRIPTION
ANI Pharmaceuticals focuses on developing, manufacturing, and marketing branded and generic prescription medicines, particularly those with complex formulations or specialized manufacturing requirements. The company specializes in niche and limited-source generic products, often acquiring and revitalizing neglected drugs, which can face fewer competitors. ANI Pharmaceuticals is a specialty pharmaceutical firm emphasizing unique or underserved drug markets, leveraging its capabilities in regulatory navigation and complex drug manufacturing.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 316.4M | 486.8M | 614.4M | 883.4M | 40.8% | 978.4M | 1.1B | 1.2B | 18.0% |
| EPS | -3.05 | 0.86 | -1.04 | 3.50 | 101.7% | 4.59 | 4.12 | 4.63 | 15.0% |
| Shares | 17.5M | 20.5M | 21.1M | 22.5M | +28.6% | 23.0M | — | — | — |
| Debt | 286.5M | 285.7M | 624.1M | 617.0M | 29.1% | 626.0M | — | — | — |
| Equity | 338.5M | 457.6M | 428.5M | 540.7M | 16.9% | — | — | — | — |
| Op CF | -31.2M | 119.0M | 64.0M | 185.2M | 24.8% | 189.5M | — | — | — |
| Inv CF | -15.7M | -18.5M | -404.7M | -34.3M | — | — | — | — | — |
| Fin CF | -5.1M | 67.4M | 264.9M | -9.9M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of ANIP are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| ANIP | ANI Pharmaceuticals, Inc.(you) | $1.7B | 92 | Strong Buy |
| GTII.CN | Green Thumb Industries Inc. | $1.6B | 94 | Strong Buy |
| TRLV | Trulieve Cannabis Corp. | $2.3B | 90 | Strong Buy |
| BCRX | BioCryst Pharmaceuticals, Inc. | $2.5B | 85 | Strong Buy |
| AMPH | Amphastar Pharmaceuticals, Inc. | $936M | 95 | Strong Buy |
| PCRX | Pacira BioSciences, Inc. | $1.0B | 85 | Strong Buy |
| PAHC | Phibro Animal Health Corporation | $1.5B | 74 | Buy |
| ETON | Eton Pharmaceuticals, Inc. | $1.7B | 72 | Buy |
| INDV | Indivior Pharmaceuticals, Inc. | $4.1B | 94 | Strong Buy |
| IRWD | Ironwood Pharmaceuticals, Inc. | $682M | 100 | Strong Buy |
Peer medians: ROE -30.8% · P/E 27.1x · Gross margin 58.1%